Tags

Type your tag names separated by a space and hit enter

YAZ and the novel progestin drospirenone.
J Reprod Med 2008; 53(9 Suppl):721-8JR

Abstract

Drospirenone is a novel progestin that is structurally related to 17 alpha-spirolactone and has antimineralocorticoid and antiandrogenic activity. A 3-mg dose of drospirenone was first used in combination with ethinyl estradiol (EE) 30 microg in a combination oral contraceptive (COC) that is administered for 21 days, followed by a 7-day hormone-free interval (HFI) (drospirenone/30EE, or Yasmin). The 21/7 regimen is considered to be the standard regimen for COC delivery. A formulation with the metabolic benefit of COCs containing a lower estrogen dose has been developed combining drospirenone 3 mg with EE 20 microg and using a regimen of 24 days of active pills, followed by a 4-day HFI (drospirenone/20EE-24/4), or YAZ (Bayer HealthCare Pharmaceuticals Inc., Wayne, New Jersey). Since drospirenone has a half-life of > 30 hours, its activity extends for a prolonged time into the shortened HFI. This new COC has been shown to provide effective contraception and to have a good safety profile. Two large noninterventional studies have recently evaluated the safety of drospirenone/30EE in 2 areas of special interest: hyperkalemia and thromboembolic events. Use of a drospirenone-containing COC was not associated with an increased risk of either type of disorder in comparison with COCs containing other progestins. Drospirenone/20EE-24/4 provides a low dose of EE in combination with drospirenone in an effective and safe COC that is administered using a regimen with a shortened HFI. Drospirenone/20EE-24/4 is the only COC with 3 indications: contraception and the treatment of premenstrual dysphoric disorder in women who wish to use a COC for birth control, and the treatment of moderate acne in women who are at least 14-years-old, have achieved menarche and wish to use a COC for birth control.

Authors+Show Affiliations

Department of Obstetrics and Gynecology, Keck School of Medicine, University of Southern California, Los Angeles, CA 90033, USA. mishell@usc.edu

Pub Type(s)

Journal Article

Language

eng

PubMed ID

18980044

Citation

Mishell, Daniel R.. "YAZ and the Novel Progestin Drospirenone." The Journal of Reproductive Medicine, vol. 53, no. 9 Suppl, 2008, pp. 721-8.
Mishell DR. YAZ and the novel progestin drospirenone. J Reprod Med. 2008;53(9 Suppl):721-8.
Mishell, D. R. (2008). YAZ and the novel progestin drospirenone. The Journal of Reproductive Medicine, 53(9 Suppl), pp. 721-8.
Mishell DR. YAZ and the Novel Progestin Drospirenone. J Reprod Med. 2008;53(9 Suppl):721-8. PubMed PMID: 18980044.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - YAZ and the novel progestin drospirenone. A1 - Mishell,Daniel R,Jr PY - 2008/11/5/pubmed PY - 2009/1/27/medline PY - 2008/11/5/entrez SP - 721 EP - 8 JF - The Journal of reproductive medicine JO - J Reprod Med VL - 53 IS - 9 Suppl N2 - Drospirenone is a novel progestin that is structurally related to 17 alpha-spirolactone and has antimineralocorticoid and antiandrogenic activity. A 3-mg dose of drospirenone was first used in combination with ethinyl estradiol (EE) 30 microg in a combination oral contraceptive (COC) that is administered for 21 days, followed by a 7-day hormone-free interval (HFI) (drospirenone/30EE, or Yasmin). The 21/7 regimen is considered to be the standard regimen for COC delivery. A formulation with the metabolic benefit of COCs containing a lower estrogen dose has been developed combining drospirenone 3 mg with EE 20 microg and using a regimen of 24 days of active pills, followed by a 4-day HFI (drospirenone/20EE-24/4), or YAZ (Bayer HealthCare Pharmaceuticals Inc., Wayne, New Jersey). Since drospirenone has a half-life of > 30 hours, its activity extends for a prolonged time into the shortened HFI. This new COC has been shown to provide effective contraception and to have a good safety profile. Two large noninterventional studies have recently evaluated the safety of drospirenone/30EE in 2 areas of special interest: hyperkalemia and thromboembolic events. Use of a drospirenone-containing COC was not associated with an increased risk of either type of disorder in comparison with COCs containing other progestins. Drospirenone/20EE-24/4 provides a low dose of EE in combination with drospirenone in an effective and safe COC that is administered using a regimen with a shortened HFI. Drospirenone/20EE-24/4 is the only COC with 3 indications: contraception and the treatment of premenstrual dysphoric disorder in women who wish to use a COC for birth control, and the treatment of moderate acne in women who are at least 14-years-old, have achieved menarche and wish to use a COC for birth control. SN - 0024-7758 UR - https://www.unboundmedicine.com/medline/citation/18980044/YAZ_and_the_novel_progestin_drospirenone_ DB - PRIME DP - Unbound Medicine ER -